Joshua D. Mitchell

Joshua D. Mitchell

Auto-generated profile, based on publicly available information

Joshua D. Mitchell

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Annals of Oncology
Verified
Journal Article
Closed access
GCGiuseppe Curigliano
Giuseppe Curigliano
DLD. Lenihan
D. Lenihan
MFM. Fradley
M. Fradley
SGS. Ganatra
S. Ganatra
ABA. Barac
A. Barac
KJK. Jordan
K. Jordan

14 December 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JHJoerg Herrmann
Joerg Herrmann
DLDaniel Lenihan
Daniel Lenihan
SASaro Armenian
Saro Armenian
ABAna Barac
Ana Barac
ABAnne Blaes
Anne Blaes
PVPeter Valent
Peter Valent
The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

1 March 2011 in JACC
Verified
Journal Article
Closed access
EHEdward A. Hulten
Edward A. Hulten
SCSalvatore Carbonaro
Salvatore Carbonaro
SPSara P. Petrillo
Sara P. Petrillo
JMJoshua D. Mitchell
Joshua D. Mitchell
TVTodd Villines
Todd Villines

1 December 2018 in JACC
Verified
Journal Article
Closed access
JMJoshua D. Mitchell
Joshua D. Mitchell
NFNicole Fergestrom
Nicole Fergestrom
BGBrian F. Gage
Brian F. Gage
RPRobert Paisley
Robert Paisley
PMPatrick Moon
Patrick Moon
TVTodd C. Villines
Todd C. Villines

1 December 2018 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
JMJoshua D. Mitchell
Joshua D. Mitchell
RPRobert Paisley
Robert Paisley
PMPatrick Moon
Patrick Moon
ENEric Novak
Eric Novak
TVTodd Villines
Todd Villines

23 July 2009 in Heart
Verified
Journal Article
Closed access
PDF file
EHE Hulten
E Hulten
JMJ Mitchell
J Mitchell
JSJ Scally
J Scally
BGB Gibbs
B Gibbs
TVT C Villines
T C Villines
Context: Patients with HIV may have increased risk of atherosclerotic cardiovascular disease owing to multiple biological mechanisms. Objective: To evaluate the evidence for subclinical atherosclerosis among patients with HIV. Design: Systematic review of observational studies. Data sources: We searched Medline, Cochrane DSR, ACP Journal Club, DARE, CMR, HTA, NHSEED, Embase and the Cochrane Controlled Trials Register for studies published before November 2008. Study selection: Eligible studies were cross-sectional, cohort, or case–control studies reporting carotid ultrasound intima-media thickness (CIMT), focal plaque incidence, or coronary artery calcium (CAC), as determined by HIV positivity or protease inhibitor (PI) exposure. Data extraction: Two independent reviewers abstracted data using a standardised form. The primary outcome was weighted mean difference (WMD) for CIMT comparing HIV positive versus negative patients. Other outcomes included WMD by PI exposure and the odds ratio (OR) for a focal carotid plaque or CAC. Data from six cross-sectional, seven case–control and 13 cohort studies were included, involving 5456 HIV positive and 3600 HIV negative patients. Results: The weighted mean CIMT was 0.04 mm thicker among patients with HIV than among non-HIV patients (95% CI 0.02 to 0.06; p<0.001). HIV positivity was not associated with carotid plaque or CAC. PI exposure did not significantly affect CIMT, carotid plaque, or CAC. There was evidence of publication bias and stratified analysis and meta-regression showed outcomes were influenced by study design, age, gender and smoking. However, HIV positivity slightly increased CIMT even after sensitivity analyses. Conclusions: HIV infection and PI exposure are not strong independent risk factors for subclinical atherosclerosis. Confounding may contribute to overestimation of the risk associated with HIV and PI exposure.